Sentence examples for trail to target from inspiring English sources

Here, we tested the ability of TRAIL to target cell cycle-arrested tumor cells.

Attempts have been undertaken to improve delivery of TRAIL to target cells and its therapeutic efficacy [ 15].

The second benefit is the ability of TRAIL to target cancer cells with specificity, allowing for induction of apoptosis by p53-independent mechanisms while avoiding toxicity to the host observed with TNF- α (Takeda et al, 2007).

To search for novel strategies to target the apoptosis signaling pathways for the treatment of glioblastoma, we investigated the combination of ABT-737 and TRAIL to target the intrinsic and extrinsic pathways of apoptosis in the present study.

Similarly, Grisendi et al [ 78] used adipose tissue-derived MSCs that were transduced with TNF-related apoptosis-inducing ligand (TRAIL) to target several xenograft models of cancer, including cervical, pancreatic and colon cancer.

As glioblastoma cell lines predominately express TRAIL-R2, we selected a human monoclonal antibody specifically directed against TRAIL-R2 (Drozitumab) to target the TRAIL signaling pathway.

136, 162 In contrast, when more cancer-specific therapeutics such as monoclonal antibodies and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are applied to target CTCs, such systemic toxicity may be less of a concern.

Both CD95 and TRAIL are potential candidates to target apoptosis in malignant cells (Debatin and Krammer, 2004; Papenfuss et al, 2008; Russo et al, 2010).

The recognition of the overwhelming importance of Fc γRII/Fc γRIIB binding for the agonistic activity of most TNFRSF receptor-specific IgGs may revitalize/enhance efforts to target the TRAIL death receptors in cancer therapy with antibody variants with Fc γRIIB-binding properties superior to the antibodies used so far.

Subsequently, Loebinger et al. [6] used MSCs expressing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to conduct magnetic target therapy against lung metastases and gained desirable clinical efficacy.

Molecular and biological features of the cell lines, including susceptibility to TRAIL and to target-specific inhibitors, are listed in Supplementary Table S1.